BML-111

BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2) . BML-111 has antiangiogenic, antitumor and anti-inflammatory properties[1][2].

Product Specifications

CAS Number

[78606-80-1]

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin-converting Enzyme (ACE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/bml-111.html

Purity

98.87

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=C(OC)CCC[C@H](O)[C@H](O)CO

Molecular Formula

C8H16O5

Molecular Weight

192.21

Precautions

H302, H315, H319, H335

References & Citations

[1]Ying Chen, et al. Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis. Mol Cancer Ther. 2010 Aug;9 (8) :2164-74.|[2]Qiong-Feng Chen, et al. BML-111, a Lipoxin Receptor Agonist, Protects Against Acute Injury via Regulating the Renin Angiotensin-Aldosterone System. Prostaglandins Other Lipid Mediat. 2019 Feb;140:9-17.|[3]T H Lee, et al. Inhibition of Leukotriene B4-induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships. Biochem Biophys Res Commun. 1991 Nov 14;180 (3) :1416-21.